Increased MYBL2 expression in aggressive hormone‐sensitive prostate cancer
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13314
Abstract: Loss of the histone demethylase KDM5D (lysine‐specific demethylase 5D) leads to in vitro resistance of prostate cancer cells to androgen deprivation therapy (ADT) with and without docetaxel. We aimed to define downstream drivers of the KDM5D… read more here.
Keywords: prostate cancer; prostate; expression; hormone sensitive ... See more keywords
De Novo, Progressed, and Neglected Metastatic Castration‐Sensitive Prostate Cancer: Is One Therapy Fit for All?
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Genitourinary Cancer"
DOI: 10.1016/j.clgc.2018.07.014
Abstract: &NA; Patients who receive a diagnosis of metastatic castration‐sensitive prostate cancer (CSPC) have different phenotypes of disease. Some of them have de novo CSPC, but others receive a late diagnosis, and still others underwent prostatectomy… read more here.
Keywords: castration sensitive; prostate cancer; metastatic castration; sensitive prostate ... See more keywords
Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
Sign Up to like & getrecommendations! Published in 2018 at "European journal of cancer"
DOI: 10.1016/j.ejca.2018.08.010
Abstract: AIM Androgen deprivation therapy (ADT) has long been the gold standard for patients with metastatic hormone-sensitive prostate cancer (mHSPC). Clinical trials have demonstrated significant survival benefits when docetaxel (DOC) or abiraterone acetate (AA) and prednisone… read more here.
Keywords: prostate; hormone sensitive; metastatic hormone; sensitive prostate ... See more keywords
Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard.
Sign Up to like & getrecommendations! Published in 2017 at "European urology"
DOI: 10.1016/j.eururo.2017.09.029
Abstract: Addition of docetaxel to androgen deprivation therapy (ADT) was recommended for patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), who are fit enough to receive docetaxel. Two recently published trials showed that the addition… read more here.
Keywords: abiraterone acetate; prostate cancer; hormone sensitive; metastatic hormone ... See more keywords
Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer.
Sign Up to like & getrecommendations! Published in 2020 at "European urology"
DOI: 10.1016/j.eururo.2020.06.033
Abstract: Recently, mutations in speckle-type pox virus and zinc finger protein (SPOP) gene (mutant SPOP [mtSPOP]) have been associated with improved outcomes to abiraterone in the castration-resistant setting. We hypothesized that mtSPOP would be associated with… read more here.
Keywords: men novo; castration sensitive; novo metastatic; metastatic castration ... See more keywords
How I Treat Metastatic Hormone-Sensitive Prostate Cancer?
Sign Up to like & getrecommendations! Published in 2021 at "Indian Journal of Medical and Paediatric Oncology"
DOI: 10.1055/s-0041-1729725
Abstract: Androgen deprivation therapy (ADT) combined with docetaxel or antiandrogens (abiraterone, enzalutamide, or apalutamide) improved the outcomes in men with metastatic hormone-sensitive prostate cancer (mHSPC). When multiple options are available, the dilemma remains how to choose… read more here.
Keywords: metastatic hormone; sensitive prostate; prostate cancer; hormone sensitive ... See more keywords
Prognostic impact of sarcopenia in patients with metastatic hormone-sensitive prostate cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Japanese journal of clinical oncology"
DOI: 10.1093/jjco/hyaa045
Abstract: BACKGROUND Cancer cachexia is associated with a poor prognosis. This study aimed to investigate the association between sarcopenia and survival in patients with metastatic hormone-sensitive prostate cancer. METHODS We retrospectively evaluated 197 patients diagnosed with… read more here.
Keywords: prostate cancer; hormone sensitive; metastatic hormone; sensitive prostate ... See more keywords
Systemic therapy in metastatic hormone-sensitive prostate cancer
Sign Up to like & getrecommendations! Published in 2022 at "Current Opinion in Supportive and Palliative Care"
DOI: 10.1097/spc.0000000000000622
Abstract: Purpose of review The landscape of metastatic hormone sensitive prostate cancer (mHSPC) has evolved rapidly in recent years with new data from landmark trials supporting upfront treatment intensification. The developments come not only on the… read more here.
Keywords: metastatic hormone; prostate cancer; therapy; hormone sensitive ... See more keywords
External validation of the prostascore model in patients with metastatic hormone‐sensitive prostate cancer recruited to the CHAARTED study
Sign Up to like & getrecommendations! Published in 2018 at "BJU International"
DOI: 10.1111/bju.14138
Abstract: To externally validate ‘prostascore’ in patients with metastatic hormone‐sensitive prostate cancer recruited to the phase III CHAARTED study. read more here.
Keywords: prostate cancer; patients metastatic; hormone sensitive; cancer recruited ... See more keywords
Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration‐sensitive prostate cancer
Sign Up to like & getrecommendations! Published in 2018 at "BJU International"
DOI: 10.1111/bju.14642
Abstract: To identify biomarkers that predict the response to standard androgen deprivation therapy (ADT) of patients newly diagnosed with metastatic castration‐sensitive prostate cancer (CSPC) in order to improve therapeutic decision‐making, and to investigate whether the characterization… read more here.
Keywords: castration sensitive; prostate cancer; metastatic castration; circulating tumour ... See more keywords
Impact of Gleason pattern 5 on prognosis for newly diagnosed metastatic hormone‐sensitive prostate cancer with Gleason score ≥8
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Urology"
DOI: 10.1111/iju.14781
Abstract: We evaluated the impact of Gleason pattern 5 presence on prognosis among de novo metastatic hormone‐sensitive prostate cancer patients with a Gleason score ≥8. read more here.
Keywords: impact gleason; metastatic hormone; hormone sensitive; gleason pattern ... See more keywords